Y.D. More Investments Ltd lessened its position in shares of InMode Ltd. (NASDAQ:INMD - Free Report) by 34.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 190,051 shares of the healthcare company's stock after selling 98,313 shares during the quarter. Y.D. More Investments Ltd owned about 0.23% of InMode worth $4,227,000 as of its most recent SEC filing.
A number of other hedge funds have also recently added to or reduced their stakes in the company. Meitav Investment House Ltd. grew its stake in InMode by 22.1% during the 4th quarter. Meitav Investment House Ltd. now owns 1,940,890 shares of the healthcare company's stock worth $43,166,000 after buying an additional 351,863 shares during the last quarter. LSV Asset Management grew its stake in InMode by 3,557.6% during the 3rd quarter. LSV Asset Management now owns 1,678,819 shares of the healthcare company's stock worth $51,137,000 after buying an additional 1,632,919 shares during the last quarter. Boston Trust Walden Corp purchased a new position in shares of InMode in the 4th quarter valued at approximately $32,366,000. DDD Partners LLC grew its stake in shares of InMode by 24.4% in the 4th quarter. DDD Partners LLC now owns 1,228,162 shares of the healthcare company's stock valued at $27,314,000 after purchasing an additional 240,856 shares during the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd grew its stake in shares of InMode by 44.0% in the 3rd quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,080,000 shares of the healthcare company's stock valued at $32,897,000 after purchasing an additional 330,000 shares during the last quarter. Hedge funds and other institutional investors own 68.04% of the company's stock.
Wall Street Analyst Weigh In
INMD has been the topic of several analyst reports. Needham & Company LLC reiterated a "hold" rating on shares of InMode in a research note on Tuesday, April 9th. UBS Group lifted their target price on InMode from $24.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, February 14th. Finally, Barclays lowered their target price on InMode from $34.00 to $33.00 and set an "overweight" rating on the stock in a research note on Friday, April 12th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $32.80.
Read Our Latest Stock Report on INMD
InMode Stock Up 0.3 %
Shares of InMode stock traded up $0.05 during trading on Wednesday, reaching $17.24. The company's stock had a trading volume of 1,570,525 shares, compared to its average volume of 1,554,800. InMode Ltd. has a 12-month low of $16.82 and a 12-month high of $48.25. The company has a market capitalization of $1.45 billion, a P/E ratio of 7.50 and a beta of 2.16. The business has a 50 day moving average price of $20.06 and a 200-day moving average price of $21.40.
InMode (NASDAQ:INMD - Get Free Report) last posted its quarterly earnings results on Tuesday, February 13th. The healthcare company reported $0.71 earnings per share for the quarter, beating analysts' consensus estimates of $0.66 by $0.05. InMode had a return on equity of 29.80% and a net margin of 40.22%. The firm had revenue of $126.80 million for the quarter, compared to the consensus estimate of $124.77 million. During the same period in the previous year, the business earned $0.69 earnings per share. The company's revenue for the quarter was down 5.1% compared to the same quarter last year. Research analysts predict that InMode Ltd. will post 2.04 EPS for the current fiscal year.
InMode Company Profile
(
Free Report)
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
See Also
Before you consider InMode, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InMode wasn't on the list.
While InMode currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
